hVIVO Chairman Cathal Friel shares his thoughts on £13.6m contract

hVIVO plc (LON:HVO) announced that it has signed a £13.6m contract with a US-based biopharmaceutical client to test its respiratory syncytial virus antiviral candidate, using hVIVO’s established RSV Human Challenge Study Model.

“I am delighted to announce that hVIVO has signed another significant challenge study contract, this time a £13.6m contract with a US based biopharma company. 

We are delighted to see the continuous growing demand for human challenge trials from both new and existing customers. As the team outlined at last week’s Capital Markets Day, as the global pharma and biotech players learn more about the many benefits of human challenge trials, not only are the number of contracts increasing, but the size of these contracts are growing significantly also. As the world leader in human challenge trials, we are delighted to see this growth. 

Chairman Cathal Friel “

The Phase 2a double-blinded placebo-controlled human challenge trial will take place at the Company’s specialist quarantine facilities in Whitechapel and will evaluate the efficacy profile of the antiviral against RSV infection. The study is expected to commence in Q3/Q4 2023, with the revenue being recognised in 2023 and 2024. As part of the study, hVIVO will recruit healthy volunteers via the Company’s dedicated volunteer recruitment arm, FluCamp.

This contract highlights hVIVO’s world leading expertise in its field and its ability to execute sizable contracts as well as the industry’s renewed focus on developing new treatments for RSV. The Company continues to see growing demand for larger challenge studies from both new and existing clients as they seek greater clarity of data and pursue lower frequency endpoints in an effort to further de-risk their programmes ahead of later stage field studies.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Share on facebook
    Share on twitter
    Share on linkedin
    hVIVO plc

    More articles like this

    hVIVO plc

    The lowdown on Norovirus

    Norovirus (or the vomiting bug) is a highly contagious disease characterised by diarrhoea, vomiting, and stomach pain. Symptoms typically develop 12 to 48 hours after being exposed to the virus and usually last one to three days. Norovirus and influenza

    hVIVO plc

    hVIVO plc to present at the World Vaccine Congress, Washington D.C.

    hVIVO plc (Euronext / LON:HVO), (formerly Open Orphan plc) a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, has announced that Dr Andrew Catchpole, Chief Scientific Officer, will be

    hVIVO plc

    Respiratory Syncytial Virus in babies

    What is respiratory syncytial virus (RSV) in children? RSV is a respiratory virus that causes illness and trouble breathing. It is more common in winter and early spring months and can be which can be life-threatening in babies and

    hVIVO plc

    The history of the Flu Vaccine from 1940 to 2030

    In 1918, about 50 million people, or one-fifth of the world’s population, became infected with the virus known as the “Spanish” flu, according to the Centers for Disease Control and Prevention (CDC). “The 1918 Pandemic was the reason the military was

    hVIVO plc

    Can asthma sufferers exercise?

    Asthma sufferers will often avoid exercise, fearing that it will worsen their condition or induce an asthma attack. Whilst it can be the case that exercise triggers symptoms, this should not be a reason for it to be

    hVIVO plc

    hVIVO Omicron human challenge agent has been successfully manufactured

    hVIVO plc (LON:HVO), (formerly Open Orphan plc) a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, has announced that its Omicron human challenge agent has

    hVIVO plc

    Where is Influenza most commonly found in the world?

    Influenza isn’t just limited to certain areas of the world. The flu virus leads to nearly 40 million flu-related illnesses each year even though it is one of the most preventable diseases. It can be found in Asia and

    hVIVO plc

    UK CRO hVIVO second Asia Pacific client in 2023

    hVIVO has signed a new testing contract with an Asia-Pacific based drug maker, which it says is an indication of its growing regional client base. The UK contract research organisation (CRO) shared minimal details of the £6.8 million

    hVIVO plc

    10 Features of the ATMPs development

    There are several distinctive features that must be considered in the ATMP development: ATMPs are mainly for the unmet medical needs = severe, rare, or chronic diseases with no adequate conventional treatments. Risk-based approach = Dominant strategy of

    hVIVO plc

    Infinite possibilities for drug development

    Over 25 years Venn Life Sciences have built up substantial therapeutic and study experience, contributing to the efficient management of sites, budgets and communication channels. Venn is renowned for its hands-on approach and consistent delivery of high quality

    The small drug firms set to benefit from RSV vaccines

    Here’s an investment idea that starts with large blue-chip companies, but has significant trickle-down potential to at least three smaller, growth companies listed in the UK. Chances are RSV, or respiratory syncytial virus, which has symptoms similar to

    hVIVO plc

    Accelerated regulatory pathways: Vaccines for tropical diseases

    Reproduced from an online seminar presentation, made in collaboration with TOPRA and hVIVO, given on 21 June 2022 by Bruno Speder from hVIVO. Despite advancement in global pharmaceutical research, nearly one billion individuals are affected by tropical diseases yearly,

    hVIVO plc

    Irish-founded hVIVO lands €7.5m contract to test vaccines

    hVIVO, an Irish-founded research organisation, has signed a major contract worth £6.8 million (€7.6 million) to test vaccines. The company, formerly known as Open Orpahn, said the deal was with a “leading pharmaceutical company based in Asia Pacific”,

    hVIVO plc

    Stock Watch – Hvivo

    Hvivo landed its second contract this year with a pharmaceutical company based in Asia Pacific. The AIM-listed clinical trial specialist has identified the region as a ‘key growth area’. As part of a £6.8million deal, Hvivo will recruit

    hVIVO plc

    hVIVO signs £6.8m RSV contract with second APAC client

    hVIVO plc (LON:HVO), (formerly Open Orphan plc) a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that it has signed a £6.8m contract with

    hVIVO plc

    Venn Life Sciences €3.2m contract win with global pharma company

    hVIVO plc (formerly Open Orphan plc) is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials, providing end-to-end early clinical development services

    No more posts to show